Brain tumors in S100β-v-erbB transgenic rats

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 12, 2006, Pages 1111-1117

  Ohgaki, Hiroko ^a   Kita, Daisuke ^a   Favereaux, Alexandre ^a   Huang, Herve ^a   Homma, Taku ^a   Dessen, Pierre ^a   Weiss, William A ^b   Kleihues, Paul ^c   Heppner, Frank L ^d  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Brain tumor; Epidermal growth factor receptor (EGFR); Transgenic rats; v erbB

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN S 100; PROTEIN S 100 BETA; HYBRID PROTEIN; NERVE GROWTH FACTOR; ONCOPROTEIN; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT; TUMOR MARKER;

ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BRAIN; CELL TRANSFORMATION; DISEASE MODEL; FEMALE; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; METHODOLOGY; OLIGODENDROGLIOMA; PATHOLOGY; PATHOPHYSIOLOGY; PROMOTER REGION; TRANSGENE; TRANSGENIC ANIMAL; WISTAR RAT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLIOMA; MALE; NERVE GROWTH FACTORS; OLIGODENDROGLIOMA; ONCOGENE PROTEINS V-ERBB; PROMOTER REGIONS (GENETICS); RATS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; S100 PROTEINS; TRANSFECTION; TRANSGENES; TUMOR MARKERS, BIOLOGICAL;

EID: 33845360642     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000248544.28423.48     Document Type: Article

References (51)

1. Gutmann DH, Baker SJ, Giovannini M, Garbow J, Weiss W. Mouse models of human cancer consortium symposium on nervous system tumors. Cancer Res 2003;63:3001-4
2. Ding H, Roncari L, Shannon P, et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001;61:3826-36
3. Ding H, Shannon P, Lau N, et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 2003;63:1106-13
4. Weiss WA, Burns MJ, Hackett C, et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 2003;63:1589-95
5. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1; Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000;26:109-13
6. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307:521-27
7. Schatzman RC, Evan GI, Privalsky ML, Bishop JM. Orientation of the v-erb-B gene product in the plasma membrane. Mol Cell Biol 1986;6:1329-33
8. Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 1999;11:162-67
9. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998;4:148-58
10. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-24
11. Riederer BM, Innocenti GM. MAP2 isoforms in developing cat cerebral cortex and corpus callosum. Eur J Neurosci 1992;4:1376-86
12. Fan QW, Zhang C, Shokat KM, Weiss WA. Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Curr Biol 2002;12:1386-94
13. Bomhard E. Frequency of spontaneous tumors in Wistar rats in 30-months studies. Exp Toxicol Pathol 1992;44:381-92
14. Haas MJ, Dragan YP, Hikita H, et al. Transgene expression and repression in transgenic rats bearing the phosphoenolpyruvate carboxykinase-simian virus 40 T antigen or the phosphoenolpyruvate carboxykinase-transforming growth factor-alpha constructs. Am J Pathol 1999;155:183-92
15. Watson PA, Kim K, Chen KS, Gould MN. Androgen-dependent mammary carcinogenesis in rats transgenic for the Neu proto-oncogene. Cancer Cell 2002;2:67-79
16. Davies BR, Platt-Higgins AM, Schmidt G, Rudland PS. Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats. Am J Pathol 1999;155:303-14
17. Shikishima H, Ikeda H, Yamada S, et al. HTLV-I pX transgenic rats: Development of cytokine-producing mammary carcinomas and establishment of the pX mammary carcinoma cell lines. Leukemia 1997;11:70-72
18. Kikuchi K, Ikeda H, Tsuchikawa T, et al. A novel animal model of thymic tumour: Development of epithelial thymoma in transgenic rats carrying human T lymphocyte virus type I pX gene. Int J Exp Pathol 2002;83:247-55
19. Asamoto M, Hokaiwado N, Cho YM, et al. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 2001;61:4693-700
20. Dragan YP, Sargent LM, Babcock K, Kinunen N, Pitot HC. Alterations in specific gene expression and focal neoplastic growth during spontaneous hepatocarcinogenesis in albumin-SV40 T antigen transgenic rats. Mol Carcinog 2004;40:150-59
21. Tsuda H, Asamoto M, Ochiya T, et al. High susceptibility of transgenic rats carrying the human c-Ha-ras proto-oncogene to chemically-induced mammary carcinogenesis. Mutat Res 2001;477:173-82
22. Asamoto M, Toriyama-Baba H, Ohnishi T, et al. Transgenic rats carrying human c-Ha-ras proto-oncogene are highly susceptible to N- nitrosomethylbenzylamine induction of esophageal tumorigenesis. Jpn J Cancer Res 2002;93:744-51
23. Pfeifer A. Lentiviral transgenesis. Transgenic Res 2004;13:513-22
24. Hamra FK, Gatlin J, Chapman KM, et al. Production of transgenic rats by lentiviral transduction of male germ-line stem cells. Proc Natl Acad Sci U S A 2002;99:14931-36
25. Tesson L, Cozzi J, Menoret S, et al. Transgenic modifications of the rat genome. Transgenic Res 2005;14:531-46
26. Janisch W. Tumours of the central nervous system. In: Turusov VS, Mohr U, eds. Tumours of the Rat. Lyon: International Agency for Research on Cancer, 1990:677-98
27. Snell KC. Spontaneous lesions of the rat. In: Ribelin WE, McCoy JR, eds. Pathology of Laboratory Animals. Springfield, IL: Charles C. Thomas, 2005:241-302
28. Kleihues P, Wiestler OD, Ohgaki H, Aguzzi A. Animal models of tumors of the nervous system. In: Berger MS, Wilson C, eds. The Gliomas. Philadelphia: WB Saunders, 1998:124-33
29. Zook BC, Simmens SJ, Jones RV. Evaluation of ENU-induced gliomas in rats: nomenclature, immunochemistry, and malignancy. Toxicol Pathol 2000;28:193-201
30. Vaquero J, Coca S, Moreno M, et al. Expression of neuronal and glial markers in so-called oligodendroglial tumors induced by transplacental administration of ethyl-nitrosourea in the rat. Histol Histopathol 1992;7:647-51
31. Burger PC, Shibata T, Aguzzi A, Kleihues P. Selective induction by N-nitrosoethylurea of oligodendrogliomas in fetal forebrain transplants. Cancer Res 1988;48:2871-75
32. Nikitin AY, Ballering LA, Lyons J, Rajewsky MF. Early mutation of the neu(erbB-2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage. Proc Natl Acad Sci U S A 1991;88:9939-43
33. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000:29-39
34. Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004;14:131-36
35. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 1996;149:29-35
36. McLendon RE, Wikstrand CJ, Matthews MR, Al Baradei R, Bigner SH, Bigner DD. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 2000;48:1103-10
37. Jiang H, Shah S, Hilt DC. Organization, sequence, and expression of the murine S100 beta gene. Transcriptional regulation by cell type-specific cis-acting regulatory elements. J Biol Chem 1993;268:20502-11
38. Deloulme JC, Raponi E, Gentil BJ, et al. Nuclear expression of S100B in oligodendrocyte progenitor cells correlates with differentiation toward the oligodendroglial lineage and modulates oligodendrocytes maturation. Mol Cell Neurosci 2004;27:453-65
39. Rickmann M, Wolff JR. S100 immunoreactivity in a subpopulation of oligodendrocytes and Ranvier's nodes of adult rat brain. Neurosci Lett 1995;186:13-16
40. Hachem S, Aguirre A, Vives V, Marks A, Gallo V, Legraverend C. Spatial and temporal expression of S100B in cells of oligodendrocyte lineage. Glia 2005;51:81-97
41. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-99
42. Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System, 2nd ed. Lyon: International Agency for Research on Cancer, 2000
43. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8:1197-206
44. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-611
45. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70
46. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990;87:4207-11
47. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96
48. Cavenee WK. Genetics and new approaches to cancer therapy. Carcinogenesis 2002;23:683-86
49. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992;89:4309-13
50. Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification- rearrangement in human glioblastomas. Int J Cancer 1995;62:145-48
51. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24